ERBB2 and benign neoplasm: Of 80 studies, 8 reported the expression of HER2/neu in benign tumors, 78 studies reported the expression of HER2/neu in malignant tumors, 65 used evaluation methods for IHC used to assess HER2 in malignant salivary gland tumors (Group 1), and the remaining 13 used a variety of methods with different cut off points and scoring scales (Group 2).